Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure

American Journal of Cardiology

Volumn 86, Issue 8, 2000, Pages 886-889

  Whorlow, Sarah L ^a   Krum, Henry ^a  

^a Clinical Pharmacology Unit   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; METOPROLOL;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG TOLERABILITY; HEART PERFORMANCE; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RR INTERVAL;

ADRENERGIC BETA-ANTAGONISTS; BENZOPYRANS; BISOPROLOL; CARBAZOLES; ETHANOLAMINES; HEART FAILURE, CONGESTIVE; HUMANS; METOPROLOL; PROPANOLAMINES;

EID: 0034662777     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01114-0     Document Type: Article

References (23)

1. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 83:1999;2A-38A.
2. Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure . Lancet. 353:1999;2001-2007.
3. Fisher M.L., Gottlieb S.S., Plotnick G.D., Greenberg N.L., Patten R.D., Bennett S.K., Hamilton B.P. Beneficial effects of metoprolol in heart failure associated with coronary artery disease a randomized trial . J Am Coll Cardiol. 23:1994;943-950.
4. Waagstein F., Bristow M.R., Swedberg K., Camerini F., Fowler M.B., Silver M.A., Gilbert E.M., Johnson M.R., Goss F.G., Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 42:1993;1441-1446.
5. Gilbert E.M., Anderson J.L., Deitchman D., Yanowitz F.G., O'Connell J.B., Renlund D.G., Bartholomew M., Mealey P.C., Larrabee P., Bristow M.R. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy a double-blind, randomised study of bucindolol versus placebo . Am J Med. 88:1990;223-229.
6. Woodley S.L., Gilbert E.M., Anderson J.L., O'Connell J.B., Deitchman D., Yanowitz F.G., Mealey P.C., Volkman K., Renlund D.G., Menlove R., Bristow M.R. β-Blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 84:1991;2426-2441.
7. Bristow M.R., O'Connell J.B., Gilbert E.M., French W.J., Leatherman G., Kantrowitz N.E., Orie J., Smucker M.L., Marshall G., Kelly P., et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 89:1994;1632-1642.
8. Uhlir O., Dvorak I., Gregor P., Malek I., Spinarova L., Vojacek J., Van Neueter L. Nebivolol in the treatment of cardiac failure a double-blind controlled clinical trial . J Card Fail. 3:1997;271-276.
9. Wisenbaugh T., Katz I., Davis J., Essop R., Skoularigis J., Middlemost S., Röthlisberger C., Skudicky D., Sareli P. Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol. 21:1993;1094-1100.
10. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet. 349:1997;375-380.
11. Packer M., Colucci W.S., Sackner-Bernstein J.D., Liang C., Goldsher D.A., Freeman I., Kukin M.L., Kinhal V., Udelson J.E., Klapholz M., Gottlieb S.S., Pearle D., Cody R.J., Gregory J.J., Kantrowitz N.E., LeJemtel T.H., Young S.T., Lukas M.A., Susterman N.H. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation. 94:1996;2793-2799.
12. Krum H., Sackner-Berstein J.D., Goldsmith R.L., Kukin M.L., Schwartz B., Penn J., Medina N., Yushak M., Horn E., Katz S.D., Levin H.R., Neuberg G.W., DeLong G., Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 92:1995;1499-1506.
13. Colucci W.S., Packer M., Bristow M.R., Gibert E.M., Cohn J.N., Fowler M.B., Krueger S.K., Hershberger R., Uretshy B.F., Bowers J.A., Sackner Bernstein J.D., Young S.T., Holcslaw T.L., Lukas A.M. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806.
14. Bristow M., Gilbert E.M., Abraham W.T., Adams K.F., Fowler M.B., Hershberger R.E., Kubo S.H., Narahara K.A., Ingersoll H., Krueger S., Young S., Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
15. Cohn J.N., Fowler M.B., Bristow M.B., Colucci W.S., Gilbert E.M., Kinhal V., Krueger S.K., LeJemtel T.H., Narahara K.A., Packer M., Young S.T., Holcslaw T.L., Lukas M.A. Safety and efficacy of carvedilol in severe heart failure. J Card Fail. 3:1997;173-179.
16. Metra M., Nardi M., Biubbini R., Deilas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 24:1994;1678-1687.
17. Olsen S.L., Gilbert E.M., Renlund D.G., Taylor D.O., Yanowitz F.D., Bristow M.R. Carvedilol improves left ventricular function and symptoms in chronic heart failure a double-blinded randomized study . J Am Coll Cardiol. 25:1995;1225-1231.
18. A randomized trial of β-blockade in heart failure the Cardiac Insufficiency Bisoprolol Study . Circulation. 90:1994;1765-1773.
19. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II) a randomised trial . Lancet. 353:1999;9-13.
20. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
21. Macdonald P.S., Keogh A.M., Aboyoun C.L., Lund M., Amor R., McCaffrey D.J. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol. 33:1999;924-931.
22. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 341:1999;709-717.
23. Willette R.N., Mitchell M.P., Ohlstein E.H., Lukas M.A., Ruffolo R.R. Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart. Pharmacology. 56:1998;30-36.